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ABSTRACT 
The pharmaceutical industry faces a multitude of new challenges. Consumers are reluctant to spend 
more on healthcare, while their expectations grow. Healthcare providers use new methods to deliver 
better care for less money. Simultaneously, while these new methods will reshape the pharmaceutical 
industry, short-term profit pressure threatens the industry. These factors are pushing the 
pharmaceutical industry towards a much harder competition than it was used to. 
 
In order to overcome the hurdles of this competitive climate, two broad strategies can be identified for 
pharmaceutical companies. The first strategy suggests a merger or acquisition, which appear to be the 
best answer to short-term pressure as well as to potential long-term pipeline gaps. For many 
companies an operational improvement program seems to be a feasible alternative strategy. In order to 
be successful with the chosen strategy, the management and protection of knowledge becomes a 
crucial success factor. 
 
In the traditional paradigm of drug discovery, identifying new compounds was slow and expensive. 
Lacking a rapid and systematic approach for generating and screening compounds, pharmaceutical 
companies were able to discover and test only a small number of drugs. Cost control demands and 
time-line acceleration restricted the number of drug-variations analysed, which narrowed the data 
obtained to support a patent filing. Consequently, patents were written narrowly. Although patenting is 
essential, many pharmaceutical companies treat it more as a defensive rather than a strategic weapon 
to protect knowledge. 
 
Patents around broader intellectual property spaces become apparent, even if the legal and regulatory 
side is still unclear. This new type of patents opens a tremendous opportunity. If they are upheld, they 
will fundamentally change the basis of competition. The value of a first-mover position will increase. 
Even if they are only partially upheld, patent strategies that create new and broader intellectual 
property are likely to enable pharmaceutical companies to lay claim to large segments of the market 
and effectively block out competitors. 
 
Information technology is already critical to successful drug discovery. New methods require to 
process enormous amount of data. This amount of data will boost with an increasing share patenting. 
A truly innovative company will use information technology not only for data analysis but also to 
access information from internal and external sources to its employees. The winner in this industry 
would be the company that manages, accesses and interprets its information most intelligently. 
 
The progress of science and technology, which is mainly a result of the highly competitive business 
environment, is likely to erode the old paradigm within the pharmaceutical industry. The increasing 
amount of information requires a proactive system to enable the protection and management of 
knowledge. The role of intellectual property in the pharmaceutical industry, as an outcome of 
knowledge management, transforms patenting from a supportive role into a strategic weapon to fight 
competition with. Hence, competition is shifting upwards along the value chain from the product 
towards the earlier stage of knowledge. The knowledge leaders are likely to conquer the value of 
tomorrow’s market, while the followers risk to be closed out. 
